Heron Therapeutics, Inc. (HRTX) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $1.28 (+7.50%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jun 9, 2025 | Brandon Folkes | H.C. Wainwright | $6.00 | +366.9% |
| May 16, 2024 | Carl Byrnes | Northland Securities | $9.00 | +600.4% |
| Mar 13, 2024 | Serge Belanger | Needham | $5.00 | +289.1% |
Top Analysts Covering HRTX
HRTX vs Sector & Market
| Metric | HRTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +419.1% | +1149.8% | +14.9% |
| P/E Ratio | -9.99 | 6.88 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $42M | $43M | $44M | 2 |
| 2026-09-30 | $44M | $45M | $46M | 1 |
| 2026-12-31 | $49M | $50M | $51M | 1 |
| 2027-12-31 | $204M | $210M | $217M | 1 |
| 2028-12-31 | $247M | $254M | $262M | 2 |
| 2029-12-31 | $287M | $296M | $304M | 1 |
| 2030-12-31 | $319M | $329M | $338M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.01 | $-0.00 | $-0.00 | 1 |
| 2026-09-30 | $-0.00 | $-0.00 | $-0.00 | 1 |
| 2026-12-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2027-12-31 | $0.13 | $0.13 | $0.14 | 1 |
| 2028-12-31 | $0.21 | $0.30 | $0.39 | 2 |
| 2029-12-31 | $0.35 | $0.36 | $0.37 | 1 |
| 2030-12-31 | $0.42 | $0.44 | $0.46 | 1 |
Frequently Asked Questions
What is the analyst consensus for HRTX?
The consensus among 1 analysts covering Heron Therapeutics, Inc. (HRTX) is Buy with an average price target of $6.67.
What is the highest price target for HRTX?
The highest price target for HRTX is $9.00, set by Carl Byrnes at Northland Securities on 2024-05-16.
What is the lowest price target for HRTX?
The lowest price target for HRTX is $5.00, set by Serge Belanger at Needham on 2024-03-13.
How many analysts cover HRTX?
1 analysts have issued ratings for Heron Therapeutics, Inc. in the past 12 months.
Is HRTX a buy or sell right now?
Based on 1 analyst ratings, HRTX has a consensus rating of Buy (2.00/5) with a +419.1% upside to the consensus target of $6.67.
What are the earnings estimates for HRTX?
Analysts estimate HRTX will report EPS of $-0.00 for the period ending 2026-06-30, with revenue estimated at $43M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.